VNUS Medical Technologies Corporation

VNUS Medical Technologies First-Quarter 2008 Results Call
Apr 21, 2008 at 2:00 PM PT
Due to teleconference vendor technical problems, the question-and-answer session for the VNUS First-Quarter Teleconference did not take place as planned. Interested parties who have any questions are invited to contact the company at ir@vnus.com.

VNUS Stock Quote

Current Price:	$16.02
Change	- 1.48% 0.24
Day High	$16.29
Day Low	$15.99
Volume	57,300

4:09 PM ET on May 16, 2008
Quote delayed at least 20 minutes.

Legal Counsel
Latham & Watkins LLP

Independent Accountants
PricewaterhouseCoopers LLP

Transfer Agent
Computershare Trust Company, N.A.
350 Indiana Street, Suite 800
Golden, CO 80401
Phone: 800-962-4284
Fax: 303-262-0700

Investor Relations
Demer IR
408-360-7499 Extension 7446
ir@vnus.com

Corporate Profile

VNUS Medical Technologies, Inc. is a leading provider of medical devices for the minimally invasive treatment of symptomatic venous reflux disease. This disease is a progressive condition caused by incompetent vein valves and subsequently inadequate return of blood from the legs to the heart, resulting in pain, swelling, fatigue, skin ulcers, and painful varicose veins.

VNUS has developed and commercialized its proprietary Closure system for the treatment of patients who suffer from these symptoms. The Closure system consists of a radiofrequency (RF) generator and disposable catheters used to close diseased veins through the application of temperature-controlled RF energy. In a randomized clinical trial, this system was proven to be as effective as vein stripping, an open surgical procedure that has been the historical standard for treatment, with fewer side effects and faster recovery.

VNUS first deployed the Closure system in Europe in 1998 and began marketing it in the U.S. the following year. To date, more than 250,000 VNUS Closure procedures have been performed worldwide. The Closure procedure is currently accepted by the policies of approximately 100 health insurers, representing more than 220 million covered patients in the U.S. Published population studies indicated that approximately 25 million people in the U.S. and 40 million people in western Europe suffer from symptomatic venous reflux disease.

The company was founded and incorporated in 1995, and completed its initial public offering of common stock on October 20, 2004. In the offering, VNUS and selling stockholders sold a total of 5.4 million shares at a price of $15.00 per share. The company's common stock trades on the Nasdaq National Market under the ticker symbol, "VNUS".

For more information, pleased refer to the other pages of this website. For an investor information kit, please contact VNUS Investor Relations at the phone number or email address listed on this page.

Recent Releases

Disclaimer

This website may include statements concerning VNUS' operations, prospects, strategies, financial condition, and future economic performance, and demand for VNUS' products or services, as well as its intentions, plans and objectives, that are forward-looking statements. When used on the website, words like "anticipates," "expects," "believes," "estimates," "seeks," "plans," "intends," and similar expressions are intended to identify forward-looking statements designed to fall within securities law safe harbors for forward looking statements. Our expectations and beliefs regarding these matters may not materialize because these statements are based on a number of assumptions and estimates which are subject to significant uncertainties, many of which are beyond our control. Actual results may differ materially from the forward-looking statements contained in this website based on a number of factors affecting VNUS' business, including, among other things, changing competitive, market and regulatory conditions; changes in reimbursement levels established by governmental and third-party payors; the ability of VNUS to develop its products; the need for governmental clearances or approvals before selling products; the ability of VNUS to protect its patent position; the effectiveness of advertising and other promotional campaigns; the timely and successful implementation of strategic initiatives; the results of pending or future clinical trials; and overall economic conditions and general market conditions. Therefore, the reader is cautioned not to rely on these forward-looking statements. VNUS expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Additional information concerning these forward-looking statements and the factors affecting VNUS' business can be found in press releases issued by VNUS and VNUS' periodic public filings with the Securities and Exchange Commission (SEC). Copies of VNUS' press releases, SEC filings and additional information about VNUS are available on this website.

This website and the information contained herein do not constitute an offer or a solicitation of an offer for sale of any securities. None of the information contained herein is intended to be, and shall not be deemed to be, incorporated into any of VNUS' securities-related filings or documents.